trending Market Intelligence /marketintelligence/en/news-insights/trending/uYDbfP4hghjEYCLOL04j4w2 content esgSubNav
In This List

InVivo Therapeutics director to resign

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


InVivo Therapeutics director to resign

InVivo Therapeutics Holdings Corp. said that Jeffrey Hatfield will resign from the board and its audit and compensation committees, effective Dec. 31.

Hatfield's resignation is not due to any conflict or disagreement with the company or its board, InVivo Therapeutics said in a Dec. 10 regulatory document.

InVivo Therapeutics is a research and clinical-stage biomaterials and biotechnology company that develops scaffolding devices for spinal cord injuries.